Introduction
Methods
Study Design and Patients
Statistical Analyses
Results
Patient Disposition and Baseline Characteristics
Reason for discontinuation (in >1% patients) | All-Rx (n = 6051) n (%) | New-Rx (n = 2557) n (%) |
---|---|---|
From registrya, any reason | 1809 (29.9) | 905 (35.4) |
Lost to follow-up | 874 (14.4) | 491 (19.2) |
Lack of efficacy | 89 (1.5) | 56 (2.2) |
Withdrew consent | 355 (5.9) | 156 (6.1) |
Death | 70 (1.2) | 25 (1.0) |
Non-compliance | 86 (1.4) | 49 (1.9) |
Other | 333 (5.5) | 116 (4.5) |
From registry drugb, any reason | 2981 (49.3) | 1496 (58.5) |
AE | 170 (2.8) | 87 (3.4) |
SAE or SAE of interest | 101 (1.7) | 40 (1.6) |
Lost to follow-up | 399 (6.6) | 226 (8.8) |
Lack of efficacy | 1101 (18.2) | 610 (23.9) |
Intolerance | 44 (0.7) | 35 (1.4) |
Withdrew consent | 117 (1.9) | 59 (2.3) |
Other | 445 (7.4) | 220 (8.6) |
Unknown reason | 668 (11.0) | 268 (10.5) |
Demographic or characteristic | All-Rx (n = 6051) | New-Rx (n = 2557) |
---|---|---|
Sex, n (%) | ||
Male | 3489 (57.7) | 1380 (54.0) |
Female | 2562 (42.3) | 1177 (46.0) |
Racea, n (%) | ||
White | 5268 (87.3) | 2223 (87.1) |
Black | 178 (2.9) | 65 (2.5) |
Asian | 259 (4.3) | 106 (4.2) |
American Indian/Alaska native | 16 (0.3) | 7 (0.3) |
Native Hawaiian or other Pacific Islander | 40 (0.7) | 25 (1.0) |
Other | 253 (4.2) | 115 (4.5) |
Multi-race | 22 (0.4) | 12 (0.5) |
Psoriatic arthritis, n (%) | Not analyzedb
| 867 (34.0)c
|
Family history of psoriasis, n (%)* | Not analyzedb
| 1067 (41.9)d
|
PGAe, n (%) | ||
Clear | 731 (12.1) | 53 (2.1) |
Minimal | 1177 (19.5) | 141 (5.5) |
Mild | 1149 (19.1) | 310 (12.2) |
Moderate | 1781 (29.6) | 1118 (44.0) |
Severe | 973 (16.2) | 749 (29.5) |
Very severe | 213 (3.5) | 172 (6.8) |
Age, years, median (range) | 47.0 (18–94) | 46.0 (18–91) |
Weight, kg, median (range) | 87.0 (41–252)f
| 86.0 (41–218)g
|
BMI, kg/m2, median (range) | 29.4 (16–77)h
| 29.4 (16–70)i
|
Duration of psoriasisj, years, median (range) | Not analyzedb
| 13.4 (0–68)k
|
Medical history in ≥5% of patients and other history of interest | New-Rx (n = 2557) | |
---|---|---|
Cardiovascular, n (%) | ||
Hypertension | 568 (22.2) | |
Coronary artery disease | 51 (2.0) | |
Myocardial infarction | 30 (1.2) | |
Cardiac arrhythmia | 21 (0.8) | |
Angina | 19 (0.7) | |
Congestive heart failure | 8 (0.3) | |
Cerebrovascular accident | 6 (0.2) | |
Gastrointestinal, n (%) | ||
Gastroesophageal reflux disease | 165 (6.5) | |
Inflammatory bowel disease | 14 (0.5) | |
Metabolic | ||
Hyperlipidemia | 295 (11.5) | |
Diabetes mellitus | 249 (9.7) | |
Hypothyroidism | 142 (5.6) | |
Obesity | 48 (1.9) | |
Infections | ||
Tuberculosis | 28 (1.1) | |
Malignancy | ||
Cancer | 24 (0.9) | |
Neurologic and psychiatric | ||
Depression | 247 (9.7) | |
Anxiety disorder | 133 (5.2) |
Safety
AE of interest E (E/100PY) | Overall exposure to ADA at the onset of AE (years) | Overall | |||||||
---|---|---|---|---|---|---|---|---|---|
0–<1a
| 1–<2 | 2–<3 | 3–<4 | 4–<5 | 5–<6 | 6–<7 | ≥7b
| ||
N
| 6051 | 4820 | 4069 | 3561 | 2891 | 2276 | 1570 | 765 | 6051 |
PY | 5401.4 | 4403.5 | 3804.2 | 3246.5 | 2572.4 | 1945.9 | 1176.7 | 1109.5 | 23660.1 |
AE | 1712 (31.7) | 911 (20.7) | 852 (22.4) | 726 (22.4) | 413 (16.1) | 236 (12.1) | 142 (12.1) | 168 (15.1) | 5160 (21.8) |
AE leading to d/c of ADA | 168 (3.1) | 71 (1.6) | 59 (1.6) | 43 (1.3) | 37 (1.4) | 10 (0.5) | 14 (1.2) | 7 (0.6) | 409 (1.7) |
Serious AE | 245 (4.5) | 182 (4.1) | 182 (4.8) | 142 (4.4) | 121 (4.7) | 65 (3.3) | 44 (3.7) | 54 (4.9) | 1035 (4.4) |
Serious infection | 64 (1.2) | 44 (1.0) | 43 (1.1) | 28 (0.9) | 30 (1.2) | 17 (0.9) | 10 (0.8) | 11 (1.0) | 247 (1.0) |
Oral candidiasis | 7 (0.1) | 1 (<0.1) | 1 (<0.1) | 0 | 0 | 0 | 0 | 0 | 9 (<0.1) |
Active tuberculosis | 3 (<0.1) | 1 (<0.1) | 1 (<0.1) | 0 | 1 (<0.1) | 0 | 0 | 0 | 6 (<0.1) |
Opportunistic infection, otherc
| 1 (<0.1) | 0 | 0 | 0 | 1 (<0.1) | 0 | 1 (<0.1) | 0 | 3 (<0.1) |
Malignancy | 53 (1.0) | 44 (1.0) | 40 (1.1) | 36 (1.1) | 30 (1.2) | 15 (0.8) | 12 (1.0) | 17 (1.5) | 247 (1.0) |
Congestive heart failure | 3 (<0.1) | 1 (<0.1) | 2 (<0.1) | 3 (<0.1) | 1 (<0.1) | 0 | 1 (<0.1) | 0 | 11 (<0.1) |
Lupus-like reactions and systemic lupusd
| 6 (0.1) | 0 | 0 | 2 (<0.1) | 0 | 0 | 0 | 0 | 8 (<0.1) |
Demyelinating disorder | 2 (<0.1) | 0 | 2 (<0.1) | 0 | 0 | 1 (<0.1) | 0 | 0 | 5 (<0.1) |
AE leading to death | 8 (0.1) | 8 (0.2) | 4 (0.1) | 5 (0.2) | 2 (<0.1) | 0 | 2 (0.2) | 2 (0.2) | 31 (0.1) |